Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today it has initiated the ENDEAVOUR Phase 3 clinical
trial of revusiran in transthyretin (TTR)-mediated familial amyloidotic
cardiomyopathy (FAC). FAC is one of the predominant clinical
manifestations of TTR-mediated amyloidosis (ATTR), and afflicts an
estimated 40,000 people worldwide.
for Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis investment picks